Centre Paul Strauss
- Address
- lock Available on a paid plan
Centre Paul Strauss - Head and Neck Cancer Research
Centre Paul Strauss is actively advancing the treatment of head and neck malignancies through innovative combination therapy approaches. The center specializes in evaluating novel immunotherapy and radiotherapy protocols designed to improve outcomes for patients with complex oncological conditions.
- Squamous cell carcinoma of the head and neck treatment optimization
- Immunotherapy-radiotherapy combination protocols using durvalumab
- Regional tumor control strategies with targeted cervical lymph node management
A key focus of the center's research involves investigating durvalumab combined with precision radiotherapy for patients with T1-T4 N0-N2b squamous cell carcinoma of the head and neck. This innovative approach targets the primary tumor and invaded cervical lymph nodes while evaluating the feasibility of omitting prophylactic irradiation to uninvolved nodal regions, potentially reducing treatment-related toxicity while maintaining regional disease control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Paul Strauss
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Chemotherapy with Cyclophosphamide, Doxorubicin, and Docetaxel in ER-Positive HER2-Negative Breast Carcinoma in Women Over 70 | Unicancer | Phase III | Not Recruiting | Apr 2012 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 4 | Unknown | 2017-09-14 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.